Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.250
+0.140 (4.50%)
Apr 14, 2026, 3:19 PM EDT - Market open
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,488,206
Profits / Employee
-$1,340,430
Market Cap
7.45M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Processa Pharmaceuticals | 12 |
| MetaVia | 8 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| PharmaCyte Biotech | 2 |
| Addex Therapeutics | 2 |
XBIO News
- 4 weeks ago - Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Accesswire
- 5 months ago - Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Accesswire
- 6 months ago - Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Accesswire
- 8 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Accesswire
- 9 months ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Accesswire
- 9 months ago - Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire